OS Therapies Incorporated (OSTX)
OSTX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | OSTX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2024 |
| SEC CIK | 0001795091 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $205K cash; operating cash flow -$4.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 46,125,825 (2026-08-12); 31,891,933 a year earlier. | Cover page 2026-08-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-08-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MaloneBailey, LLP, Houston, Texas, United States | PCAOB Form AP 2026-04-20 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$8.6M | -$5.5M | $205K | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$10.4M | -$4.6M | $918K | $1.3M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$13.5M | -$3.7M | $270K | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$6.9M | -$4.7M | $1.9M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$4.5M | -$2.4M | $2.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$3.9M | -$3.4M | $3.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$3.0M | -$2.4M | $5.5M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$2.9M | -$3.4M | $1.9M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B7 | 2026-09-10 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-31 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-12 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-07-24 |
Source: SEC EDGAR submissions feed, 248 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -25.5% |
| 1 month | -48.6% |
| 3 months | -53.4% |
| Year to date | -46.8% |
| 1 year | -59.1% |
| From 52-week high | -66.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals Inc. | $0.4810 | -1.96% | $35.4M |
| VERU | Veru Inc. | $2.08 | -0.48% | $35.5M |
| ATHE | Alterity Therapeutics Limited | $1.96 | 0.00% | $35.7M |
| RNTX | Rein Therapeutics Inc. | $0.4000 | -27.55% | $34.5M |
| GRCE | Grace Therapeutics Inc. | $1.75 | -3.31% | $36.8M |
| SER | Serina Therapeutics Inc. | $1.42 | +2.16% | $37.7M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier